Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980116 | 0.90 | MAPK14 (0.73) | MAPK14 | |
| SCHEMBL1356209 | 0.86 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL1356502 | 0.82 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL1358719 | 0.79 | MAPK14 (0.85) | MAPK14 | |
| SCHEMBL600705 | 0.78 | MAPK14 (0.73) | MAPK14 | |
| SCHEMBL1357597 | 0.77 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL2671638 | 0.76 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL1358213 | 0.75 | MAPK14 (0.86) | MAPK14 | |
| SCHEMBL14852862 | 0.74 | MAPK14 (0.76) | MAPK14 | |
| SCHEMBL1312054 | 0.71 | MAPK14 (0.75) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420649-B2 | Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-04-16 | — | — | US | claimed |
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2011-11-17 | — | — | US | claimed |
| EP-2334673-A1 | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010025202-A1 | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | MAPK1, MAPK3, MAP4K2 | MAPK14 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.